The latest price target for Infinity Pharmaceuticals Inc (OTC:INFI) was reported by Piper Sandler on February 24, 2023. The analyst firm set a price target for $0.00 expecting INFI to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Infinity Pharmaceuticals Inc (OTC:INFI) was provided by Piper Sandler, and Infinity Pharmaceuticals Inc downgraded their neutral rating.

The last upgrade for Infinity Pharmaceuticals Inc happened on August 2, 2021 when JP Morgan raised their price target to $6. JP Morgan previously had a neutral for Infinity Pharmaceuticals Inc.

The last downgrade for Infinity Pharmaceuticals Inc happened on February 24, 2023 when Piper Sandler changed their price target from N/A to N/A for Infinity Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Infinity Pharmaceuticals Inc, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Infinity Pharmaceuticals Inc was filed on February 24, 2023 so you should expect the next rating to be made available sometime around February 24, 2024.

While ratings are subjective and will change, the latest Infinity Pharmaceuticals Inc (INFI) rating was a downgraded with a price target of $0.00 to $0.00. The current price Infinity Pharmaceuticals Inc (INFI) is trading at is $0.02, which is out of the analyst’s predicted range.